Member Info for ratcliffewriter

A pat on the back to all in the "glee club" for 2023 and beyond. Long may this board remain no place for any balanced and informative discussion, as it has done for so many years.

There could certainly be some very extravagant midnight meetings on the hilltop. The goat will need to be in good form for sure.

TF - I didn't 'invoke', I quoted - here are the exact words used to describe this board - 'a continual pat on the back “ glee club” with no place for any balanced and informative discussion.'
Go research.
Meanwhile I'm off for a mutual back-patting session with roses, GF, C7, Inanaco, WTP and other club members as we await the rapidly approaching fruits of many years of realistic research and patience.

I agree Roses, but then again we're just a gang of happy clappy back slappers aren't we?

https://www.bbc.co.uk/news/world-asia-china-64102176

Echoing much of the below, 2022 has produced more high profile progress than many previous years, and no need for any dilemma between getting rich versus positive feelings for cancer patients - the two go hand in hand, but if push came to shove then success with Moditope etc is worth more than wealth.
So here's hoping 2023 yields great returns in all areas, and I have to say how entertaining the discussions have been here. Sad that some describe LSE as 'a continual pat on the back “ glee club” with no place for any balanced and informative discussion but no matter' - they must miss out on a lot of sensible posting, but each to their own. All the best!

Never mind all that imaginery 6p lifestyle company fiction, I'm too excited waiting for Santa Claus now.

Genmab 'Looking to Improve Immunotherapy Response.' Now who could be helping with that I wonder?

'...and a marked absence of the doom squad.'

As usual with Scancell, any RNS will come when the information is good and ready, complete and checked. But don't forget that the original SCIB1 combination trial with Keith Flaherty's endorsement was released around the 21st of December so there could be an RNS any time to be honest. We shall see.

Depends who you think is more powerful - chat board contributors or the Almighty. Got to make you mind up rather than blaming one and hiding behind the other.

Roses - the trouble with Christmas is they put on all the old repeats, so tedious and one knows the story inside out.

Dear pot, have a good Christmas.
Regards,
Kettle.

RP - I'm sure he has friends or associates who will help during the busy times.

A most revealing post.

MF Christmas party....
https://youtu.be/THNPmhBl-8I

The news was actually in an RNS from prior to the AGM where it read 'all three patients showed a delayed type hypersensitivity response to the vaccine, which is indicative of a T cell response, and the first patient to be assessed has shown a partial tumour response at first radiological reassessment.'
'Partial tumour response' means at least 30 percent shrinkage, but nobody seemed to pick up on this at the time, even our resident 'I work in the pharma industry and know more than you plebs' experts. Then someone did some digging and found (on a publicly viewable site) a patient who appeared to be the one referred to, a fact later confirmed by the BoD at the AGM. Couldn't be more plain and open than that. The patient then confirmed that at the next scan at the end of November, a further significant shrinkage had taken place. So while this rise has accelerated on the public info from the Macmillan site, it is most definitely in an RNS. As said before though, 'partial response' covers the initial shrinkage amount and the subsequent significant amount, so no further update required just now, and given the potentially momentous nature of the results to date (IF they are all on a similar par) I can see an enormous amount of checking and double checking being done before any RNS or press exposure is done.
You know those articles where a bio does a BBC interview and says they have seen results in flies, mice or amoebas which if replicated in humans could cure many forms of cancer? The ones which then end with 'but it will take at least 10 years and many millions of pounds to see if this works in humans? Well its possible, just possible, that we may be seeing the other end of such a project, hence any data that is published needs to be checked to the nth degree for obvious reasons. Fingers crossed....

GF - enjoy your pizza, but spare a thought for Crackin and his club who will be dining on hard cheese and sour grapes, washed down with a little whine. But enough of the pond life - onwards and upwards.

If your head is entirely in the trading world, Scancell will be one of who knows how many shares to watch, and a ten or twenty percent profit is the end result - so sell and enjoy to repeat elsewhere, however many times you can. Ten percent across ten shares makes a lot of money if you have the time and effort to work that. I have never criticised those who do, everyone has their own strategy for trying to make money and that's fine. What I find obnoxious is the individuals (who usually coagulate into teams) who use fair means and foul (more often the latter) to push a share price in the direction that suits their next buy or sell point. Those who have followed for some years will know the individuals and ringleaders to whom I refer. But those who have remained invested here, whether you have traded the many ups and downs or just built a holding, may finally be about to see the fruits of what we have seen grow over the last 10 years or so. May those who have been honest and/or loyal reap the just rewards, and above the top of all that may the likes of the lady on the Macmillan site enjoy those benefits to their greatest degree. Tomorrow it will almost certainly be one of us who may find a long dark tunnel of ultimate despair turned into a beacon of light. Well done Lindy and Richard, Scancell's ultimate stalwarts.

MOST of whom ARE on the other SIDE and always knew INANACO was wrong. I suspect and trust that some large portions of humble pie will be available for them quite soon. Whether they'll eat them is entirely another matter.